TMCnet News
Pre-Market Technical Scan on Application Software Equities -- Allscripts Healthcare Solutions, Fortinet, Innoviva, and IntuitNEW YORK, March 21, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on MDRX, FTNT, INVA, and INTU which can be accessed for free by signing up to www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com covers the Application Software space, which creates, licenses, and sells software for a variety of uses, including personal and enterprise use. Four stocks have been lined up for assessment this morning, and they are: Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX), Fortinet Inc. (NASDAQ: FTNT), Innoviva Inc. (NASDAQ: INVA), and Intuit Inc. (NASDAQ: INTU). All you have to do is sign up today for this free limited time offer by clicking the link below. www.wallstequities.com/registration Allscripts Healthcare Solutions On Tuesday, shares in Illinois headquartered Allscripts Healthcare Solutions Inc. recorded a trading volume of 2.61 million shares, which was above their three months average volume of 1.96 million shares. The stock ended the session 1.48% lower at $12.69. The Company's shares have gained 5.14% over the past year. The stock is trading 6.61% below its 200-day moving average. Moreover, shares of the Company, which provides information technology solutions and services to healthcare organizations in the US, Canada, and internationally, have a Relative Strength Index (RSI) of 30.01. On February 27th, 2018, research firm Bank of America/ Merrill resumed its 'Buy' rating on the Company's stock. On March 06th, 2018 at the annual HIMSS conference, Allscripts Healthcare Solutions unveiled its new electronic health record, Avenel™. Mobile-first and cloud-based, Avenel creates a community-wide shared patient record, uses machine learning to reduce time for clinical documentation, and is designed to work like an app instead of traditional software. Get the full research report on MDRX for free by clicking below at: www.wallstequities.com/registration/?symbol=MDRX Fortinet California headquartered Fortinet Inc.'s stock closed the day 0.81% higher at $53.78 with a total trading volume of 716,213 shares. The Company's shares have advanced 9.87% in the past month, 23.24% in the previous three months, and 45.43% over the past year. The stock is trading 11.62% and 29.58% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Fortinet, which provides broad, automated, and integrated cybersecurity solutions worldwide, have an RSI of 66.26. On March 15th, 2018, Fortinet announced the results from NSS Labs' annual Data Center Intrusion Prevention System test report. The testing revealed that both of the Company's FortiGate IPS 3000D and FortiGate IPS 7060E excelled in the areas of performance, total cost of ownership, and security effectiveness, and as a result, received NSS Labs' 'Recommended' rating. On March 19th, 2018, research firm KeyBanc Capital Markets downgraded the Company's stock rating from 'Overweight' to 'Sector Weight'. Free research on FTNT can be accessed at: www.wallstequities.com/registration/?symbol=FTNT Innoviva Shares in California headquartered Innoviva Inc. recorded a trading volume of 455,628 shares. The stock ended ysterday's trading session 0.44% higher at $16.01. The Company's shares have advanced 19.21% in the previous three months and 20.97% over the past year. The stock is trading above its 50-day and 200-day moving averages by 4.26% and 16.61%, respectively. Furthermore, shares of Innoviva, which engages in the development and commercialization of bio-pharmaceuticals, have an RSI of 53.98. On March 08th, 2018, Innoviva and GlaxoSmithKline PLC announced that the European Commission has approved a label update for the use of the once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid / long-acting ß2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting ß2-agonist. Visit WallStEquities.com now and sign up for the free research on INVA at: www.wallstequities.com/registration/?symbol=INVA Intuit California headquartered Intuit Inc.'s stock finished Tuesday's session 1.37% higher at $178.15. A total volume of 1.45 million shares was traded, which was above their three months average volume of 1.36 million shares. The Company's shares have advanced 3.76% in the last month, 11.59% over the previous three months, and 44.37% over the past year. The stock is trading above its 50-day and 200-day moving averages by 6.15% and 18.39%, respectively. Additionally, shares of Intuit, which provides financial management and compliance products and services for small businesses, consumers, self-employed, and accounting professionals in the US and internationally, have an RSI of 61.86. On February 21st, 2018, research firm Bank of America/ Merrill reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $172 a share to $185 a share. On March 19th, 2018, Intuit announced that QuickBooks Online Accountant (QBOA) now allows accounting professionals to manage all of their clients - even those that do not use QuickBooks - within the product. This innovation is now available globally for QBOA users in the US, Canada, United Kingdom, Australia, South Africa, and France. It enables accountants to organize and view client information, notes, and details in one consolidated place. Get the full report on INTU for free at: www.wallstequities.com/registration/?symbol=INTU Wall St. Equities: Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. WSE has not been compensated; directly or indirectly; for producing or publishing this document. PRESS RELEASE PROCEDURES: The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. NO WARRANTY WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. NOT AN OFFERING This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/ CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities 
|
View original content: